Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 6
2000 7
2001 16
2002 12
2003 25
2004 18
2005 14
2006 10
2007 10
2008 11
2009 17
2010 23
2011 27
2012 25
2013 33
2014 22
2015 23
2016 10
2017 14
2018 17
2019 16
2020 6
2021 4
2022 6
2023 3
2024 6
2025 14
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
At week 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0% of patients (n=293 of 315) in the dolutegravir, abacavir, and lamivudine group (difference -0.6%, …
At week 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and ten …
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Stainsby CM, Perger TM, Vannappagari V, Mounzer KC, Hsu RK, Henegar CE, Oyee J, Urbaityte R, Lane CE, Carter LM, Pakes GE, Shaefer MS. Stainsby CM, et al. Pharmacotherapy. 2019 Jan;39(1):40-54. doi: 10.1002/phar.2196. Epub 2018 Dec 11. Pharmacotherapy. 2019. PMID: 30414209 Free PMC article.
INTRODUCTION: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus trea …
INTRODUCTION: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivit …
Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.
Jesson J, Saint-Lary L, Revegue MHDT, O'Rourke J, Townsend CL, Renaud F, Penazzato M, Leroy V. Jesson J, et al. Lancet Child Adolesc Health. 2022 Oct;6(10):692-704. doi: 10.1016/S2352-4642(22)00213-9. Epub 2022 Sep 2. Lancet Child Adolesc Health. 2022. PMID: 36058225 Free PMC article.
BACKGROUND: Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. ...Data from 24 265 participants were included, of whom 7236 (30%) received abacavir. Abacavir hypersensitivity reaction was reported in nine (38%) studie …
BACKGROUND: Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. ...Data from 24 265 particip …
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Cruciani M, et al. Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Cochrane Database Syst Rev. 2013. PMID: 23740608 Free PMC article.
Several clinical trials have evaluated the efficacy of triple nucleoside combination as a simplification therapy in patients who achieved virologic suppression OBJECTIVES: The aim of this review is to combine randomised, controlled trials to examine whether in patients with undet …
Several clinical trials have evaluated the efficacy of triple nucleoside combination as a simplification therapy in patients who achieved vi …
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Orkin C, et al. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130806 Clinical Trial.
METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV- …
METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretro …
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
Jesson J, Dahourou DL, Renaud F, Penazzato M, Leroy V. Jesson J, et al. Lancet HIV. 2016 Feb;3(2):e64-75. doi: 10.1016/S2352-3018(15)00225-8. Epub 2015 Dec 7. Lancet HIV. 2016. PMID: 26847228
All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. Incidence of adverse outcomes in patients taking abacavir (number of new events in a period divided by population at risk at the beginning of the st …
All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. Incidence of ad …
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Cruciani M, et al. AIDS. 2011 Oct 23;25(16):1993-2004. doi: 10.1097/QAD.0b013e328349c6ee. AIDS. 2011. PMID: 21716077 Review.
BACKGROUND: The use of abacavir (ABC) has been associated with an increased risk of cardiovascular disease in some cohort studies. ...
BACKGROUND: The use of abacavir (ABC) has been associated with an increased risk of cardiovascular disease in some cohort studies. .. …
Once-daily abacavir in place of twice-daily administration.
Goedken AM, Herman RA. Goedken AM, et al. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1302-8. doi: 10.1345/aph.1E680. Epub 2005 Jun 14. Ann Pharmacother. 2005. PMID: 15956231 Review.
The key words used in all searches were abacavir and Ziagen. Article bibliographies were used to identify additional relevant articles. ...STUDY SELECTION AND DATA EXTRACTION: Publications were included that provided information related to the safety and efficacy of aba …
The key words used in all searches were abacavir and Ziagen. Article bibliographies were used to identify additional relevant article …
Virological efficacy of abacavir: systematic review and meta-analysis.
Cruciani M, Mengoli C, Malena M, Serpelloni G, Parisi SG, Moyle G, Bosco O. Cruciani M, et al. J Antimicrob Chemother. 2014 Dec;69(12):3169-80. doi: 10.1093/jac/dku279. Epub 2014 Jul 28. J Antimicrob Chemother. 2014. PMID: 25074854
OBJECTIVES: The efficacy of abacavir/lamivudine has been reported to be inferior to tenofovir/emtricitabine. Several randomized clinical trials (RCTs) investigated the effectiveness and safety of abacavir/lamivudine and tenofovir/emtricitabine combined antiretrovira …
OBJECTIVES: The efficacy of abacavir/lamivudine has been reported to be inferior to tenofovir/emtricitabine. Several randomized clini …
364 results